Los Alamos National Laboratory Completes Successful Analysis of Antibodies Using Lumera Corporation Technology
November 15 2006 - 8:45AM
Business Wire
Lumera Corporation (Nasdaq:LMRA), an emerging leader in the field
of nanotechnology, announced today that its proprietary Heterodimer
Protein Technology (HPT) and ProteomicProcessor� were both
successfully used to analyze single chain antibodies from Los
Alamos National Laboratory (LANL). �Lumera is pleased to work with
Los Alamos National Laboratory,� said Tom Mino, Lumera CEO. �Our
Bioscience Business Unit channels our nanotechnology platform into
developing useful tools for finding and speeding up the delivery of
the next billion-dollar therapeutic drug. This work illustrates the
versatility of the Lumera antibody discovery products, which we
plan to offer next year to the drug discovery market.� �Currently,
we are using e-coil tagged, single chain antibodies in a high
throughput flow cytometry-based screening and characterization,�
said Peter Pavlik, project leader at Los Alamos. �Having access to
Lumera�s high throughput SPR-based characterization technology that
uses the same coil chemistry would increase our ability to
characterize antibodies in great detail.� �The extraordinary
revenue growth rate of therapeutic antibodies is one of the most
attractive in the pharmaceutical industry,� said Ronald Dudek,
Director of Business Development at Lumera Corporation. �The Lumera
antibody discovery products will be the first of a suite of new
products that present a total solution to our partners in the drug
discovery market. We believe that applied nanotechnology solutions,
like those we will offer, will increase the speed and efficiency of
pharmaceutical drug discovery.� Los Alamos National Laboratory is a
world leader in phage display technology, antibody engineering, and
the development of high throughput screening assays. Phage display
is an emerging technology for the production of very large and
highly diverse antibody libraries. Antibodies are the human body�s
immune response to infection, which is typically caused by foreign
substances or antigens. Scientists have found that antibodies have
the capacity to bind specifically to antigens, thereby neutralizing
the antigen. This ability is giving rise to a very large
pharmaceutical market known as therapeutic antibodies. Rituxan, a
highly successful billion-dollar commercial drug which treats
non-Hodgkin�s lymphoma, is an example of a therapeutic antibody
drug. The LANL single chain antibodies were engineered to contain
the Lumera E-Coil peptide tag. The engineered antibodies were then
screened using the Lumera NanoCapture� K-Coil microarray slide and
ProteomicProcessor� instrument system. About Lumera Lumera is a
leader in the emerging field of nanotechnology. The company designs
proprietary molecular structures and polymer compounds for the
bioscience and communications/computing industries, both of which
represent large market opportunities. The company also has
developed proprietary processes for fabricating such devices. For
more information, please visit www.lumera.com. About Los Alamos
National Laboratory Los Alamos National Laboratory is a
multidisciplinary research institution engaged in strategic science
on behalf of national security. The Laboratory is operated by a
team composed of Bechtel National, the University of California,
BWX Technologies, and Washington Group International for the
Department of Energy's National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and
reliability of the U.S. nuclear stockpile, developing technologies
to reduce threats from weapons of mass destruction, and solving
problems related to energy, environment, infrastructure, health and
global security concerns. Certain statements contained in this
release are forward-looking statements that involve a number of
risks and uncertainties. Factors that could cause actual results to
differ materially from those projected in the company's
forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing;
our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological
change; government regulation of our technologies; our ability to
enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from
time to time in the company's SEC reports, including its Annual
Report on Form 10-K, and its Quarterly Reports on Form 10-Q. Lumera
Corporation (Nasdaq:LMRA), an emerging leader in the field of
nanotechnology, announced today that its proprietary Heterodimer
Protein Technology (HPT) and ProteomicProcessor(TM) were both
successfully used to analyze single chain antibodies from Los
Alamos National Laboratory (LANL). "Lumera is pleased to work with
Los Alamos National Laboratory," said Tom Mino, Lumera CEO. "Our
Bioscience Business Unit channels our nanotechnology platform into
developing useful tools for finding and speeding up the delivery of
the next billion-dollar therapeutic drug. This work illustrates the
versatility of the Lumera antibody discovery products, which we
plan to offer next year to the drug discovery market." "Currently,
we are using e-coil tagged, single chain antibodies in a high
throughput flow cytometry-based screening and characterization,"
said Peter Pavlik, project leader at Los Alamos. "Having access to
Lumera's high throughput SPR-based characterization technology that
uses the same coil chemistry would increase our ability to
characterize antibodies in great detail." "The extraordinary
revenue growth rate of therapeutic antibodies is one of the most
attractive in the pharmaceutical industry," said Ronald Dudek,
Director of Business Development at Lumera Corporation. "The Lumera
antibody discovery products will be the first of a suite of new
products that present a total solution to our partners in the drug
discovery market. We believe that applied nanotechnology solutions,
like those we will offer, will increase the speed and efficiency of
pharmaceutical drug discovery." Los Alamos National Laboratory is a
world leader in phage display technology, antibody engineering, and
the development of high throughput screening assays. Phage display
is an emerging technology for the production of very large and
highly diverse antibody libraries. Antibodies are the human body's
immune response to infection, which is typically caused by foreign
substances or antigens. Scientists have found that antibodies have
the capacity to bind specifically to antigens, thereby neutralizing
the antigen. This ability is giving rise to a very large
pharmaceutical market known as therapeutic antibodies. Rituxan, a
highly successful billion-dollar commercial drug which treats
non-Hodgkin's lymphoma, is an example of a therapeutic antibody
drug. The LANL single chain antibodies were engineered to contain
the Lumera E-Coil peptide tag. The engineered antibodies were then
screened using the Lumera NanoCapture(TM) K-Coil microarray slide
and ProteomicProcessor(TM) instrument system. About Lumera Lumera
is a leader in the emerging field of nanotechnology. The company
designs proprietary molecular structures and polymer compounds for
the bioscience and communications/computing industries, both of
which represent large market opportunities. The company also has
developed proprietary processes for fabricating such devices. For
more information, please visit www.lumera.com. About Los Alamos
National Laboratory Los Alamos National Laboratory is a
multidisciplinary research institution engaged in strategic science
on behalf of national security. The Laboratory is operated by a
team composed of Bechtel National, the University of California,
BWX Technologies, and Washington Group International for the
Department of Energy's National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and
reliability of the U.S. nuclear stockpile, developing technologies
to reduce threats from weapons of mass destruction, and solving
problems related to energy, environment, infrastructure, health and
global security concerns. Certain statements contained in this
release are forward-looking statements that involve a number of
risks and uncertainties. Factors that could cause actual results to
differ materially from those projected in the company's
forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing;
our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological
change; government regulation of our technologies; our ability to
enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from
time to time in the company's SEC reports, including its Annual
Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From Oct 2023 to Oct 2024